Relay Therapeutics' stock surged 6.77% during pre-market trading on Friday, following the release of its fourth quarter 2025 financial results that significantly exceeded analyst expectations.

The clinical-stage precision medicine company reported Q4 revenue of $7 million, beating the consensus estimate of $4.97 million. Additionally, Relay Therapeutics posted a narrower-than-expected net loss of $54.89 million compared to the estimated $68.1 million loss, with adjusted earnings per share of -$0.32 surpassing the -$0.42 forecast.

Investors responded positively to the company's strong cash position of $554.5 million, which provides a runway into 2029, and upcoming 2026 milestones for its lead program zovegalisib, including Phase 1/2 breast cancer data presentation at ESMO TAT in March and initial Phase 1 data in vascular anomalies expected in the first half of the year.